If you have hair loss you may be suffering from a condition called Alopecia. A new Topical cream study for ages 18 and older.
If interested, contact us at 817-755-5542 or email us at studies@acderm.com
If you have hair loss you may be suffering from a condition called Alopecia. A new Topical cream study for ages 18 and older.
If interested, contact us at 817-755-5542 or email us at studies@acderm.com
Atopic Dermatitis Sleep Disturbances
New topica creaml study for 18 years and older.
Arlington Research Center is looking for adults, aged 18 years and up who have eczema and resulting sleep disturbances, to participate in a clinical research study evaluating an investigational cream.
How can you participate?
Inquire about how you can participate in this study today.
TO LEARN MORE ABOUT THE INTEGUMENT STUDY, CONTACT:
studies@acderm.com or call 817-795-7546 ext. 339 or Text 817-755-5542.
Hidradenitis Suppurativa – upcoming study
We know life with Hidradenitis Suppurativa isn’t always easy.
There are many unanswered questions surrounding the causes of HS and the painful and distressing symptoms it triggers in the body. With limited approved medical treatment options available, it’s important to keep looking for potential answers.
Call 817-795-7546 or email studies@acderm.com if you think you would like to participate in this study.
Arlington Research Center is looking for children and adults, aged 6 years and up who have eczema, to participate in a clinical research study evaluating an investigational cream. This study includes up to 5 visits for 2 months.
Studies for youth and adults. Must have a history of atopic dermatitis for at least 3 months for youth 6-17 years of age, and for at least 6 months for adults 18 years and older. Study patients previously on the ARQ-151 are excluded.
Also have a Atopic dermatitis study with an injection medication for patients 12 years of age and older
How can you participate?
Inquire about how you can participate in this study today.
TO LEARN MORE ABOUT THE INTEGUMENT STUDY, CONTACT:
studies@acderm.com or call 817-795-7546 ext. 339 or Text 817-755-5542.
New topical study for ages 2-12 years old. This study focuses on the scalp and body.
While severe psoriasis affects the skin, causing it to itch and burn, it can also have an emotional impact on adolescents, as well as their parents.
Because of the raised, red, scaly patches on their skin, many adolescents feel ashamed or embarrassed by their condition. These emotions can cause them to not want to hang out with friends, attend school functions, or participate in extracurricular activities.
For parents watching these physical and emotional effects, it’s difficult when other treatments have not been successful in managing their child’s psoriasis.
Because many adolescents and their families struggle with psoriasis, this research study is being conducted to evaluate an investigational drug for severe psoriasis. In this study, researchers want to learn more about the safety and effectiveness of the investigational drug.
The investigational drug has not been approved by any regulatory agency for the treatment of children and adolescents with this condition. It is only available to children and adolescents in research studies like this one.
The results of this study will provide more information about the investigational drug and whether it could one day be approved for children and adolescents with severe plaque psoriasis.
Who is eligible to participate in this study?
To be eligible for this study, patients must:
All study-related visits, tests, and drugs will be provided at no cost. In addition, compensation for study-related travel may be provided.
COMING SOON!!
Topica study for ages 18-65 with warts
Call 817-795-7546 or email studies@acderm.com if you think you would like to participate in this study.
This time of year we are reminded of the gifts of Gold, Frankincense, and Myrrh – gifts fit for a king! There are actually medically beneficial properties to both Frankincense and Myrrh.
The Boswellia serrata exudate or gum (known in India as “guggulu”) that forms an aromatic resin traditionally used as incense – and known as frankincense (especially when retrieved from Boswellia species found in Eritrea and Somalia but also from the Indian variety) – has been considered for thousands of years to possess therapeutic properties. It is used in Ayurvedic medicine, as well as in traditional medicine in China and the Middle East, particularly for its anti-inflammatory effects to treat chronic conditions. In fact, such essential oils have been used since 2800 BC to treat various inflammatory conditions, including skin sores and wounds, as well as in perfumes and incense. In the West, use of frankincense dates back to thousands of years as well, more often found in the form of incense for religious and cultural ceremonies.Over the past 2 decades, evidence supporting the use of frankincense for therapeutic medical purposes has increased, particularly because of its purported anti-inflammatory and anticancer properties.
Terpenoids and essential oils are the primary components of frankincense and are known to impart anti-inflammatory and anticancer activity. The same is true for myrrh, which has been combined with frankincense in traditional Chinese medicine as a single medication for millennia, with the two acting synergistically and considered still to be a potent combination in conferring various biological benefits.
In 2010, in a systematic review of the anti-inflammatory and anticancer activities of Boswellia species and their chemical ingredients, Efferth and Oesch found that frankincense blocks the production of leukotrienes, cyclooxygenase (COX) 1 and 2, as well as 5-lipoxygenase; and oxidative stress. It also contributes to regulation of immune cells from the innate and acquired immune systems and exerts anticancer activity by influencing signaling transduction responsible for cell cycle arrest, as well as inhibition of proliferation, angiogenesis, invasion, and metastasis. The investigators also reported on clinical trial results that have found efficacy of frankincense and its constituents in ameliorating symptoms of psoriasis and erythematous eczema, among other disorders.
Another study completed in 2016 sought to identify the active ingredients responsible for the anti-inflammatory and analgesic effects of frankincense. They found that alpha-pinene, linalool, and 1-octanol were key contributors. These constituents were noted for suppressing COX-2 overexpression in mice, as well as nociceptive stimulus-induced inflammatory infiltrates.
A 2017 study evaluated the biological activities of the essential oil in pre-inflamed human dermal fibroblasts using 17 key protein biomarkers. Frankincense essential oil displayed significant antiproliferative activity and suppressed collagen III, interferon gamma-induced protein 10, and intracellular adhesion molecule 1. The investigators referred to the overall encouraging potential of frankincense essential oil to exert influence over inflammation and tissue remodeling in human skin and called for additional research into its mechanisms of action and active constituents.
The main active ingredient in frankincense, boswellic acid, has been shown to promote apoptosis, suppress matrix metalloproteinase secretion, and hinder migration in metastatic melanoma cell lines in mice. A 2019 study. demonstrated that frankincense essential oil yielded substantial antimelanoma activity in vitro and in vivo and ameliorated hepatotoxicity caused by acetaminophen.
The use of frankincense in traditional medicine has a long and impressive track record. Recent research provides reason for optimism, and further investigating the possible incorporation of this botanical agent into modern dermatologic therapies appears warranted. Clearly, however, much more research is needed.